Log In
BCIQ
Print this Print this
 

AFM13

  Manage Alerts
Collapse Summary General Information
Company Affimed N.V.
DescriptionTetravalent bispecific human antibody targeting CD30 and Fc gamma receptor IIIa (CD16a; FCGR3A; FcgammaRIIIa)
Molecular Target CD30 ; Fc gamma receptor IIIa (FCGR3A) (FcgammaRIIIa) (CD16a)
Mechanism of ActionBinds CD30; Binds CD16; Bispecific antibody
Therapeutic ModalityBiologic: Antibody

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

2

$4.4M

0

0


 Deals Details
Get a free BioCentury trial today